Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
PLoS One ; 15(3): e0228985, 2020.
Article in English | MEDLINE | ID: mdl-32150543

ABSTRACT

Parenteral Nutrition (PN) Associated Liver Disease (PNALD) affects up to 60% of neonates; however, techniques for diagnosing and monitoring disease progression remain limited. The neonatal baboon model may provide a unique opportunity to identify serologic markers associated with this disease. The purpose of this study was to investigate if Hyaluronic Acid (HA), TIMP metallopeptidase inhibitor 1 (TIMP1), Amino-terminal Propeptide of Type-III Collagen (PIIINP) and Enhanced Liver Fibrosis (ELF) score associate with histological liver disease in neonatal baboons exposed to PN. Preterm baboons delivered via c-section at 67% gestation received PN for 14 days with or without Intralipid (PRT+IL, PRT-IL, respectively) or were sacrificed after birth (PRTCTR). Term baboons were sacrificed after birth (TERMCTR) or survived 14 days (TERM+14d). Serum HA, TIMP1, and PIIINP concentrations were measured by ELISA. A blinded pathologist assigned liver histological scores following necropsy. HA increased 9.1-fold, TIMP1 increased 2.2-fold, and ELF score increased 1.4-fold in PRT-IL compared to PRTCTR. ALT, AST, and GGT were within normal limits and did not vary between groups. A trend towards increased fibrosis was found in PRT-IL baboons. Microvesicular hepatocyte steatosis and Kupffer cell hypertrophy were elevated in PRT-IL vs PRTCTR. HA and TIMP1 were significantly elevated in preterm baboons with early histological findings of liver disease evidenced by hepatic steatosis, Kupffer cell hypertrophy and a trend towards fibrosis whereas traditional markers of liver disease remained normal. These novel markers could potentially be utilized for monitoring early hepatic injury in neonates.


Subject(s)
Biomarkers/blood , Liver Diseases/metabolism , Parenteral Nutrition/adverse effects , Primate Diseases/metabolism , Animals , Animals, Newborn , Disease Models, Animal , Female , Hyaluronic Acid/blood , Kupffer Cells/pathology , Liver Diseases/etiology , Liver Diseases/pathology , Male , Papio , Premature Birth , Primate Diseases/chemically induced , Primate Diseases/pathology , Tissue Inhibitor of Metalloproteinase-1/blood
2.
Cien Saude Colet ; 16(11): 4549-66, 2011 Nov.
Article in English | MEDLINE | ID: mdl-22124833

ABSTRACT

The goal of this review was to examine whether chronic Mn exposure produces dopamine neuron degeneration and PD or whether it has a distinct neuropathology and clinical presentation. I reviewed available clinical, neuroimaging, and neuropathological studies in humans and nonhuman primates exposed to Mn or other human conditions that result in elevated brain Mn concentrations. Human and nonhuman primate literature was examined to compare clinical, neuroimaging, and neuropathological changes associated with Mn-induced parkinsonism. Clinical, neuroimaging, and neuropathological evidence was used to examine whether Mn-induced parkinsonism involves degeneration of the nigrostriatal dopaminergic system as is the case in PD. The overwhelming evidence shows that Mn-induced parkinsonism does not involve degeneration of midbrain dopamine neurons and that l-dopa is not an effective therapy. New evidence is presented on a putative mechanism by which Mn may produce movement abnormalities. Confirmation of this hypothesis in humans is essential to make rational decisions about treatment, devise effective therapeutic strategies, and set regulatory guidelines.


Subject(s)
Manganese/toxicity , Parkinson Disease, Secondary/chemically induced , Animals , Humans , Neuroimaging , Parkinson Disease, Secondary/diagnosis , Primate Diseases/chemically induced , Primate Diseases/diagnosis
3.
Ciênc. Saúde Colet. (Impr.) ; 16(11): 4519-4566, nov. 2011. ilus, tab
Article in English | LILACS | ID: lil-606576

ABSTRACT

The goal of this review was to examine whether chronic Mn exposure produces dopamine neuron degeneration and PD or whether it has a distinct neuropathology and clinical presentation. I reviewed available clinical, neuroimaging, and neuropathological studies in humans and nonhuman primates exposed to Mn or other human conditions that result in elevated brain Mn concentrations. Human and nonhuman primate literature was examined to compare clinical, neuroimaging, and neuropathological changes associated with Mn-induced parkinsonism. Clinical, neuroimaging, and neuropathological evidence was used to examine whether Mn-induced parkinsonism involves degeneration of the nigrostriatal dopaminergic system as is the case in PD. The overwhelming evidence shows that Mn-induced parkinsonism does not involve degeneration of midbrain dopamine neurons and that l-dopa is not an effective therapy. New evidence is presented on a putative mechanism by which Mn may produce movement abnormalities. Confirmation of this hypothesis in humans is essential to make rational decisions about treatment, devise effective therapeutic strategies, and set regulatory guidelines.


O objetivo desta revisão foi examinar se a exposição crônica ao Mn produz degeneração do neurônio pela dopamina e DP ou se é apenas uma apresentação neuropatológica e clínica diferente. Foram revisados estudos clínicos, de neuroimagens e neuropatológicos disponíveis sobre humanos e primatas expostos ao Mn ou outras condições humanas que resultam em concentrações elevadas de Mn no cérebro. Foi examinada a literatura sobre humanos e primatas e comparadas as mudanças clínicas de neuroimagem e neuropatológicas associadas com o "parkinsonimo" induzido por Mn, envolvendo a degeneração do sistema dopaminérgico nigro-estriatal como no caso da DP. as evidências decisivas mostram que o "parkinsonismo" induzido pelo Mn não envolve a degeneração dos neurônios de dopamina do mesencéfalo e que o dopa-1 não é uma terapia eficaz. Novas evidências estão presentes em um mecanismo putativo pelo qual o Mn pode produzir anormalidades de movimento. A confirmação desta hipótese em humanos é essencial para tomar decisões adequadas sobre o tratamento, planejar estratégias terapêuticas eficazes e estabelecer guias regulatórios.


Subject(s)
Animals , Humans , Manganese/toxicity , Parkinson Disease, Secondary/chemically induced , Neuroimaging , Parkinson Disease, Secondary/diagnosis , Primate Diseases/chemically induced , Primate Diseases/diagnosis
4.
Mol Ther ; 14(4): 564-70, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16829205

ABSTRACT

Dopamine, the major neurotransmitter depleted in Parkinson disease, can be synthesized and regulated in vivo with a combination of intrastriatal AAV-hAADC gene therapy and administration of the dopamine precursor l-Dopa. When tested in MPTP-lesioned monkeys, this approach resulted in long-term improvement in clinical rating scores, significantly lowered l-Dopa requirements, and a reduction in l-Dopa-induced side effects. Positron emission tomography with [(18)F]FMT confirmed persistent AADC activity, demonstrating for the first time that infusion of AAV vector into primate brain results in at least 6 years of transgene expression. AAV-hAADC restores the ability of the striatum to convert l-Dopa into dopamine efficiently. Introduction of this therapy into the clinic holds promise for Parkinson patients experiencing the motor complications that result from escalating l-Dopa requirements against a background of disease progression.


Subject(s)
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/pharmacology , Aromatic-L-Amino-Acid Decarboxylases/metabolism , Dependovirus/genetics , Genetic Therapy , Primate Diseases/genetics , Primate Diseases/therapy , Animals , Aromatic-L-Amino-Acid Decarboxylases/genetics , Behavior, Animal , Gene Expression , Humans , Immunohistochemistry , Levodopa/pharmacology , Macaca mulatta , Male , Positron-Emission Tomography , Primate Diseases/chemically induced , Primate Diseases/metabolism , Time Factors
5.
Nat Med ; 1(10): 1009-16, 1995 Oct.
Article in English | MEDLINE | ID: mdl-7489355

ABSTRACT

A colony of 26 chimpanzees given a fruit and vegetable diet of very low Na and high K intake were maintained in long-standing, socially stable small groups for three years. Half of them had salt added progressively to their diet during 20 months. This addition of salt within the human dietetic range caused a highly significant rise in systolic, mean and diastolic blood pressure. The change reversed completely by six months after cessation of salt. The effect of salt differed between chimpanzees, some having a large blood pressure rise and others small or no rise. These results in the species phylogenetically closest to humans bear directly on causation of human hypertension, particularly in relation to migration of preliterate people, with low Na diet, to a Western urban lifestyle with increased salt intake. The hedonic liking for salt and avid ingestion was apt during human prehistory involving hunter-gatherer-scavenger existence in the interior of continents with a scarcity of salt, but is maladaptive in urban technological life with salt cheap and freely available.


Subject(s)
Blood Pressure/drug effects , Hypertension/chemically induced , Potassium, Dietary/administration & dosage , Sodium, Dietary/administration & dosage , Animals , Blood Proteins/analysis , Body Weight , Calcium/blood , Creatinine/urine , Female , Humans , Hypertension/veterinary , Male , Pan troglodytes , Potassium/blood , Potassium/urine , Potassium, Dietary/toxicity , Primate Diseases/chemically induced , Renin/metabolism , Sodium/blood , Sodium/urine , Sodium, Dietary/toxicity
SELECTION OF CITATIONS
SEARCH DETAIL
...